The composition of the pulmonary microbiota in sarcoidosis - an observational study.
Infection
Inflammation
Interstitial lung disease
Microbiome
Sarcoidosis
Journal
Respiratory research
ISSN: 1465-993X
Titre abrégé: Respir Res
Pays: England
ID NLM: 101090633
Informations de publication
Date de publication:
28 Feb 2019
28 Feb 2019
Historique:
received:
15
01
2019
accepted:
20
02
2019
entrez:
2
3
2019
pubmed:
2
3
2019
medline:
18
6
2019
Statut:
epublish
Résumé
Sarcoidosis is a systemic disease of unknown etiology. The disease mechanisms are largely speculative and may include the role microbial patterns that initiate and drive an underlying immune process. The aim of this study was to characterize the microbiota of the lung of patients with sarcoidosis and compare its composition and diversity with the results from patients with other interstitial lung disease (ILD) and historic healthy controls. Patients (sarcoidosis, n = 31; interstitial lung disease, n = 19) were recruited within the PULMOHOM study, a prospective cohort study to characterize inflammatory processes in pulmonary diseases. Bronchoscopy of the middle lobe or the lingula was performed and the recovered fluid was immediately sent for analysis of the pulmonary microbiota by 16sRNA gene sequencing. Subsequent bioinformatic analysis was performed to compare the groups. There were no significant differences between patients with sarcoidosis or other ILDs with regard to microbiome composition and diversity. In addition, the abundance of the genera Atopobium, Fusobacterium, Mycobacterium or Propionibacterium were not different between the two groups. There were no gross differences to historical healthy controls. The analysis of the pulmonary microbiota based on 16sRNA gene sequencing did not show a significant dysbiosis in patients with sarcoidosis as compared to other ILD patients. These data do not exclude a microbiological component in the pathogenesis of sarcoidosis.
Sections du résumé
BACKGROUND
BACKGROUND
Sarcoidosis is a systemic disease of unknown etiology. The disease mechanisms are largely speculative and may include the role microbial patterns that initiate and drive an underlying immune process. The aim of this study was to characterize the microbiota of the lung of patients with sarcoidosis and compare its composition and diversity with the results from patients with other interstitial lung disease (ILD) and historic healthy controls.
METHODS
METHODS
Patients (sarcoidosis, n = 31; interstitial lung disease, n = 19) were recruited within the PULMOHOM study, a prospective cohort study to characterize inflammatory processes in pulmonary diseases. Bronchoscopy of the middle lobe or the lingula was performed and the recovered fluid was immediately sent for analysis of the pulmonary microbiota by 16sRNA gene sequencing. Subsequent bioinformatic analysis was performed to compare the groups.
RESULTS
RESULTS
There were no significant differences between patients with sarcoidosis or other ILDs with regard to microbiome composition and diversity. In addition, the abundance of the genera Atopobium, Fusobacterium, Mycobacterium or Propionibacterium were not different between the two groups. There were no gross differences to historical healthy controls.
CONCLUSION
CONCLUSIONS
The analysis of the pulmonary microbiota based on 16sRNA gene sequencing did not show a significant dysbiosis in patients with sarcoidosis as compared to other ILD patients. These data do not exclude a microbiological component in the pathogenesis of sarcoidosis.
Identifiants
pubmed: 30819175
doi: 10.1186/s12931-019-1013-2
pii: 10.1186/s12931-019-1013-2
pmc: PMC6396534
doi:
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
46Références
Lancet. 1999 Jul 10;354(9173):120-3
pubmed: 10408488
J Exp Med. 2005 Mar 7;201(5):755-67
pubmed: 15753209
Sarcoidosis Vasc Diffuse Lung Dis. 2005 Mar;22(1):33-42
pubmed: 15881278
J Immunol. 2008 Dec 15;181(12):8784-96
pubmed: 19050300
Respir Med. 2012 May;106(5):701-9
pubmed: 22349068
Clin Exp Immunol. 2013 Sep;173(3):512-22
pubmed: 23668840
PLoS One. 2013 Jul 09;8(7):e68302
pubmed: 23874580
Thorax. 2013 Dec;68(12):1150-6
pubmed: 23945167
Lancet. 2014 Mar 29;383(9923):1155-67
pubmed: 24090799
Annu Rev Physiol. 2016;78:481-504
pubmed: 26527186
Clin Chest Med. 2015 Dec;36(4):561-8
pubmed: 26593133
BMC Infect Dis. 2016 Aug 26;16(1):449
pubmed: 27562460
Microbiome. 2016 Nov 17;4(1):60
pubmed: 27855721
PLoS One. 2017 Jan 23;12(1):e0170285
pubmed: 28114394
Am J Respir Crit Care Med. 2017 Jul 15;196(2):208-219
pubmed: 28157391
MBio. 2017 Feb 14;8(1):
pubmed: 28196961
NPJ Biofilms Microbiomes. 2016 Apr 20;2:16004
pubmed: 28721243
Am J Respir Crit Care Med. 2018 Jan 15;197(2):225-234
pubmed: 28846439
Eur Respir J. 2017 Dec 14;50(6):null
pubmed: 29242257
Respir Res. 2018 Feb 27;19(1):34
pubmed: 29486761